ERBB2 and aneurysmal bone cyst: The largest and most well-conducted study regarding the combination of mCHT with anti-HER2 agents was carried out by Wildiers et al. [51] in frail ABC patients, defined by age (70 years or older and 60 years or older) but without the presence of comorbidities.